Acerca de la comunicación del INVIMA sobre riesgo de desarrollar cáncer de mama en mujeres posmenopáusicas en manejo con terapia de reemplazo hormonal (TRH) / About the communication of INVIMA of the risk of developing breast cancer in postmenopausal women receiving hormone replacement therapy (HRT)
Rev. colomb. menopaus
; 26(4): 54-59, 2020.
Article
em Es
| LILACS
| ID: biblio-1253125
Biblioteca responsável:
CO5.1
RESUMEN
Es un artículo de opinión a raíz del artículo publicado en Lancet el 29 de agosto de 2019, (Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk individual participant meta-analysis of the worldwide epidemiological evidence. DOI https//doi.org/10.1016/S0140 6736(19)31709-X.). En noviembre de 2020 el ente regulatorio colombiano, INVIMA, se pronunció sobre el aumento de riesgo de cáncer de mama asociado a TRH. De antemano se sabe que la posibilidad de desarrollar cáncer de seno asociado a TRH es muy baja y que los beneficios superan con creces ese riesgo. Es importante que se distinga las diferencias entre "asociación" y "causalidad". Se presentan todos los argumentos basados en evidencia que soportan que el riesgo con esta asociación es débil y bajo. Se analizan los resultados presentados por los ingleses, considerando que no son consistentes con lo encontrado en estudios aleatorios controlados, enmascarados y multicéntricos. Finaliza demostrando las bondades de la TRH.
ABSTRACT
This is an opinion article following the article published in Lancet on August 29, 2019, (Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk individual participant meta-analysis of the worldwide epidemiological evidence. DOI https//doi.org/10.1016/S0140 6736(19)31709-X.). On November the regulatory entity in Colombia, INVIMA, pronounced about the increased risk of breast cancer associated to HRT. It is known that the possibility of developing breast cancer under HRT is very low and that benefits overcome that risk. It is important to distinguish the differences between "association" and "causality". Al arguments are presented based on evidence that supports that the risk with this association is weak and low. The results presented by the English are analyzed, considering they are inconsistent with those found in randomized, controlled, masked and multi center trials. Ends demonstrating benefits of HRT.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
LILACS
Assunto principal:
Neoplasias da Mama
Tipo de estudo:
Clinical_trials
/
Etiology_studies
Limite:
Female
/
Humans
Idioma:
Es
Revista:
Rev. colomb. menopaus
Assunto da revista:
REPRODUCAO
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Colômbia
País de publicação:
Colômbia